Dulaglutide vs Mazdutide — mechanism, half-life, dosing, and research status compared. Which is right for your protocol?
Dulaglutide (Trulicity) is a once-weekly GLP-1 receptor agonist approved by the FDA for the treatment of type 2 diabetes and for reducing cardiovascular events in adults with T2DM or cardiovascular risk factors. It is an Fc-fusion protein consisting of two modified GLP-1 molecule...
Calculate Dulaglutide dose →Mazdutide (IBI362) is a once-weekly GLP-1/glucagon receptor dual agonist developed by Innovent Biologics. By activating both receptors simultaneously, it combines the appetite suppression and insulin-sensitizing effects of GLP-1 agonism with the fat-oxidizing and energy-expenditu...
Calculate Mazdutide dose →| Parameter | Dulaglutide | Mazdutide |
|---|---|---|
| Category | Metabolic & Mitochondrial | Metabolic & Mitochondrial |
| Research | FDA Approved | Phase III (China) |
| Half-Life | ~5 days | ~7 days |
| Typical Dose | 0.75–4.5 mg | 3–9 mg |
| Frequency | Once weekly | Once weekly |
| Route | Subcutaneous (weekly) | Subcutaneous (weekly) |
| FDA Status | Approved | Not Approved |
Use ASCEND's free reconstitution calculator to get exact syringe draw amounts for your vial.
For research use only. Not medical advice. ASCEND does not conduct or endorse any specific research protocol. Always consult relevant scientific literature and regulatory guidelines.